Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 183

1.

Bronchoalveolar lavage cell pattern from healthy human lung.

Heron M, Grutters JC, ten Dam-Molenkamp KM, Hijdra D, van Heugten-Roeling A, Claessen AM, Ruven HJ, van den Bosch JM, van Velzen-Blad H.

Clin Exp Immunol. 2012 Mar;167(3):523-31. doi: 10.1111/j.1365-2249.2011.04529.x.

2.

Post-inflammatory fatigue in sarcoidosis: personality profiles, psychological symptoms and stress hormones.

Korenromp IH, Grutters JC, van den Bosch JM, Heijnen CJ.

J Psychosom Res. 2012 Feb;72(2):97-102. doi: 10.1016/j.jpsychores.2011.10.001. Epub 2011 Nov 8.

PMID:
22281449
3.

18F-FDG PET as a predictor of pulmonary function in sarcoidosis.

Keijsers RG, Verzijlbergen EJ, van den Bosch JM, Zanen P, van de Garde EM, Oyen WJ, Grutters JC.

Sarcoidosis Vasc Diffuse Lung Dis. 2011 Oct;28(2):123-9.

PMID:
22117503
4.

Genetic variability in the IL1RN gene and the balance between interleukin (IL)-1 receptor agonist and IL-1β in idiopathic pulmonary fibrosis.

Barlo NP, van Moorsel CH, Korthagen NM, Heron M, Rijkers GT, Ruven HJ, van den Bosch JM, Grutters JC.

Clin Exp Immunol. 2011 Dec;166(3):346-51. doi: 10.1111/j.1365-2249.2011.04468.x.

5.

Lung transplantation affects expression of the chemokine receptor type 4 on specific T cell subsets.

Paantjens AW, van de Graaf EA, Kwakkel-van Erp JM, Hoefnagel T, van Kessel DA, van den Bosch JM, Otten HG.

Clin Exp Immunol. 2011 Oct;166(1):103-9. doi: 10.1111/j.1365-2249.2011.04450.x.

6.

The Induction of IgM and IgG Antibodies against HLA or MICA after Lung Transplantation.

Paantjens AW, van de Graaf EA, Kwakkel-van Erp JM, Hoefnagel T, van Ginkel WG, Fakhry F, van Kessel DA, van den Bosch JM, Otten HG.

Pulm Med. 2011;2011:432169. doi: 10.1155/2011/432169. Epub 2011 Aug 29.

7.

Mannose-binding lectin deficiency linked to cytomegalovirus (CMV) reactivation and survival in lung transplantation.

Kwakkel-van Erp JM, Paantjens AW, van Kessel DA, Grutters JC, van den Bosch JM, van de Graaf EA, Otten HG.

Clin Exp Immunol. 2011 Sep;165(3):410-6. doi: 10.1111/j.1365-2249.2011.04436.x. Epub 2011 Jun 27.

8.

Reduced Th2 cytokine production by sarcoidosis patients in clinical remission with chronic fatigue.

Korenromp IH, Grutters JC, van den Bosch JM, Zanen P, Kavelaars A, Heijnen CJ.

Brain Behav Immun. 2011 Oct;25(7):1498-502. doi: 10.1016/j.bbi.2011.06.004. Epub 2011 Jun 13.

PMID:
21693184
9.

Chimerism of dendritic cell subsets in peripheral blood after lung transplantation.

Paantjens AW, van de Graaf EA, Heerkens HD, Kwakkel-van Erp JM, Hoefnagel T, van Kessel DA, van den Bosch JM, Otten HG.

J Heart Lung Transplant. 2011 Jun;30(6):691-7. doi: 10.1016/j.healun.2011.01.706. Epub 2011 Mar 9.

PMID:
21388830
10.

Characterization of chronic fatigue in patients with sarcoidosis in clinical remission.

Korenromp IHE, Heijnen CJ, Vogels OJM, van den Bosch JMM, Grutters JC.

Chest. 2011 Aug;140(2):441-447. doi: 10.1378/chest.10-2629. Epub 2011 Feb 17.

PMID:
21330380
11.

Angiotensin II receptor type 1 1166 A/C and angiotensin converting enzyme I/D gene polymorphisms in a Dutch sarcoidosis cohort.

Kruit A, Ruven HJ, Grutters JC, van den Bosch JM.

Sarcoidosis Vasc Diffuse Lung Dis. 2010 Jul;27(2):147-52.

PMID:
21319597
12.

CA 15-3 as an alternative marker for KL-6 in fibrotic lung diseases.

Kruit A, Gerritsen WB, Pot N, Grutters JC, van den Bosch JM, Ruven HJ.

Sarcoidosis Vasc Diffuse Lung Dis. 2010 Jul;27(2):138-46.

PMID:
21319596
13.

Predicting prognosis in idiopathic pulmonary fibrosis.

Barlo NP, van Moorsel CH, van den Bosch JM, Grutters JC.

Sarcoidosis Vasc Diffuse Lung Dis. 2010 Jul;27(2):85-95. Review.

PMID:
21319590
14.

Imaging the inflammatory activity of sarcoidosis: sensitivity and inter observer agreement of (67)Ga imaging and (18)F-FDG PET.

Keijsers RG, Grutters JC, Thomeer M, Du Bois RM, Van Buul MM, Lavalaye J, Van Den Bosch JM, Verzijlbergen FJ.

Q J Nucl Med Mol Imaging. 2011 Feb;55(1):66-71. Epub 2011 Jan 18.

PMID:
21242947
15.

Genetic variation in GREM1 is a risk factor for fibrosis in pulmonary sarcoidosis.

Heron M, van Moorsel CH, Grutters JC, Huizinga TW, van der Helm-van Mil AH, Nagtegaal MM, Ruven HJ, van den Bosch JM.

Tissue Antigens. 2011 Feb;77(2):112-7. doi: 10.1111/j.1399-0039.2010.01590.x. Erratum in: Tissue Antigens. 2011 Apr;77(4):365.

PMID:
21214523
16.

Serum and BALF YKL-40 levels are predictors of survival in idiopathic pulmonary fibrosis.

Korthagen NM, van Moorsel CH, Barlo NP, Ruven HJ, Kruit A, Heron M, van den Bosch JM, Grutters JC.

Respir Med. 2011 Jan;105(1):106-13. doi: 10.1016/j.rmed.2010.09.012.

17.

Sarcoidosis HLA class II genotyping distinguishes differences of clinical phenotype across ethnic groups.

Sato H, Woodhead FA, Ahmad T, Grutters JC, Spagnolo P, van den Bosch JM, Maier LA, Newman LS, Nagai S, Izumi T, Wells AU, du Bois RM, Welsh KI.

Hum Mol Genet. 2010 Oct 15;19(20):4100-11. doi: 10.1093/hmg/ddq325. Epub 2010 Aug 3.

18.

Clara cell secretory protein and surfactant protein-D do not predict bronchiolitis obliterans syndrome after lung transplantation.

Paantjens AW, Otten HG, van Ginkel WG, van Kessel DA, van den Bosch JM, Kwakkel-van Erp JM, van de Graaf EA.

Transplantation. 2010 Aug 15;90(3):340-2. doi: 10.1097/TP.0b013e3181e1b9f8. No abstract available.

PMID:
20683434
19.

Toll-like receptor (TLR)-9 genetics and function in sarcoidosis.

Veltkamp M, Van Moorsel CH, Rijkers GT, Ruven HJ, Van Den Bosch JM, Grutters JC.

Clin Exp Immunol. 2010 Oct;162(1):68-74. doi: 10.1111/j.1365-2249.2010.04205.x. Epub 2010 Aug 19.

20.

Surfactant protein C mutations are the basis of a significant portion of adult familial pulmonary fibrosis in a dutch cohort.

van Moorsel CH, van Oosterhout MF, Barlo NP, de Jong PA, van der Vis JJ, Ruven HJ, van Es HW, van den Bosch JM, Grutters JC.

Am J Respir Crit Care Med. 2010 Dec 1;182(11):1419-25. doi: 10.1164/rccm.200906-0953OC. Epub 2010 Jul 23.

PMID:
20656946
21.

Systemic and exhaled cytokine and chemokine profiles are associated with the development of bronchiolitis obliterans syndrome.

Kastelijn EA, Rijkers GT, Van Moorsel CH, Zanen P, Kwakkel-van Erp JM, Van De Graaf EA, Van Kessel DA, Grutters JC, Van Den Bosch JM.

J Heart Lung Transplant. 2010 Sep;29(9):997-1008. doi: 10.1016/j.healun.2010.04.013. Epub 2010 Jun 8.

PMID:
20627628
22.

Surfactant protein-D predicts survival in patients with idiopathic pulmonary fibrosis.

Barlo NP, van Moorsel CH, Ruven HJ, Zanen P, van den Bosch JM, Grutters JC.

Sarcoidosis Vasc Diffuse Lung Dis. 2009 Jul;26(2):155-61.

PMID:
20560296
23.

MRP14 is elevated in the bronchoalveolar lavage fluid of fibrosing interstitial lung diseases.

Korthagen NM, Nagtegaal MM, van Moorsel CH, Kazemier KM, van den Bosch JM, Grutters JC.

Clin Exp Immunol. 2010 Aug;161(2):342-7. doi: 10.1111/j.1365-2249.2010.04181.x. Epub 2010 Jun 9.

24.

Pulmonary embolism and pulmonary infarction after lung transplantation.

Krivokuca I, van de Graaf EA, van Kessel DA, van den Bosch JM, Grutters JC, Kwakkel-van Erp JM.

Clin Appl Thromb Hemost. 2011 Aug;17(4):421-4. doi: 10.1177/1076029610371474. Epub 2010 Jun 13.

PMID:
20547546
25.

Potential role of endothelin-1 in pulmonary fibrosis: from the bench to the clinic.

Barlo NP, van Moorsel CH, Kazemier KM, van den Bosch JM, Grutters JC.

Am J Respir Cell Mol Biol. 2010 May;42(5):633. doi: 10.1165/rcmb.2009-0410OC. No abstract available.

PMID:
20393073
26.

Genetic polymorphisms in MMP7 and reduced serum levels associate with the development of bronchiolitis obliterans syndrome after lung transplantation.

Kastelijn EA, van Moorsel CH, Ruven HJ, Karthaus V, Kwakkel-van Erp JM, van de Graaf EA, Zanen P, van Kessel DA, Grutters JC, van den Bosch JM.

J Heart Lung Transplant. 2010 Jun;29(6):680-6. doi: 10.1016/j.healun.2010.01.008. Epub 2010 Mar 29.

PMID:
20347338
27.

Polymorphisms in innate immunity genes associated with development of bronchiolitis obliterans after lung transplantation.

Kastelijn EA, van Moorsel CH, Rijkers GT, Ruven HJ, Karthaus V, Kwakkel-van Erp JM, van de Graaf EA, Zanen P, van Kessel DA, Grutters JC, van den Bosch JM.

J Heart Lung Transplant. 2010 Jun;29(6):665-71. doi: 10.1016/j.healun.2009.12.013. Epub 2010 Mar 15.

PMID:
20227302
28.

Lung transplantation under a tacrolimus/mycophenolate mofetil-based immunosuppressive regimen results in low titers of HLA and MICA IgG antibodies which are not related to development of BOS.

Paantjens AW, van de Graaf EA, van Ginkel WG, van den Bosch JM, Otten HG.

J Heart Lung Transplant. 2010 May;29(5):596-8. doi: 10.1016/j.healun.2009.10.004. Epub 2010 Mar 5. No abstract available.

PMID:
20207170
29.

(18)F-FDG PET patterns and BAL cell profiles in pulmonary sarcoidosis.

Keijsers RG, Grutters JC, van Velzen-Blad H, van den Bosch JM, Oyen WJ, Verzijlbergen FJ.

Eur J Nucl Med Mol Imaging. 2010 Jun;37(6):1181-8. doi: 10.1007/s00259-009-1376-6. Epub 2010 Feb 16.

PMID:
20157709
30.

T-cell activation profiles in different granulomatous interstitial lung diseases--a role for CD8+CD28(null) cells?

Heron M, Claessen AM, Grutters JC, van den Bosch JM.

Clin Exp Immunol. 2010 May;160(2):256-65. doi: 10.1111/j.1365-2249.2009.04076.x. Epub 2009 Dec 17.

31.

Lung function in idiopathic pulmonary fibrosis--extended analyses of the IFIGENIA trial.

Behr J, Demedts M, Buhl R, Costabel U, Dekhuijzen RP, Jansen HM, MacNee W, Thomeer M, Wallaert B, Laurent F, Nicholson AG, Verbeken EK, Verschakelen J, Flower CD, Petruzzelli S, De Vuyst P, van den Bosch JM, Rodriguez-Becerra E, Lankhorst I, Sardina M, Boissard G; IFIGENIA study group.

Respir Res. 2009 Oct 27;10:101. doi: 10.1186/1465-9921-10-101.

32.

[Idiopathic pulmonary fibrosis; description of a Dutch cohort].

Barlo NP, van Moorsel CH, van den Bosch JM, van de Graaf EA, Kwakkel-van Erp JM, Grutters JC.

Ned Tijdschr Geneeskd. 2009;153:B425. Dutch.

PMID:
19785823
33.

Variation in IL7R predisposes to sarcoid inflammation.

Heron M, Grutters JC, van Moorsel CH, Ruven HJ, Huizinga TW, van der Helm-van Mil AH, Claessen AM, van den Bosch JM.

Genes Immun. 2009 Oct;10(7):647-53. doi: 10.1038/gene.2009.55. Epub 2009 Jul 23.

PMID:
19626041
34.

Effect of variation in ITGAE on risk of sarcoidosis, CD103 expression, and chest radiography.

Heron M, Grutters JC, Van Moorsel CH, Ruven HJ, Kazemier KM, Claessen AM, Van den Bosch JM.

Clin Immunol. 2009 Oct;133(1):117-25. doi: 10.1016/j.clim.2009.06.007. Epub 2009 Jul 14.

PMID:
19604725
35.

Nitric oxide diffusing capacity versus spirometry in the early diagnosis of emphysema in smokers.

van der Lee I, Gietema HA, Zanen P, van Klaveren RJ, Prokop M, Lammers JW, van den Bosch JM.

Respir Med. 2009 Dec;103(12):1892-7. doi: 10.1016/j.rmed.2009.06.005. Epub 2009 Jul 7.

36.

The Fcgamma receptor IIA-R/R131 genotype is associated with severe sepsis in community-acquired pneumonia.

Endeman H, Cornips MC, Grutters JC, van den Bosch JM, Ruven HJ, van Velzen-Blad H, Rijkers GT, Biesma DH.

Clin Vaccine Immunol. 2009 Jul;16(7):1087-90. doi: 10.1128/CVI.00037-09. Epub 2009 Jun 3.

37.

Bronchovascular fistula formation after lung transplantation.

van de Graaf EA, Kwakkel-van Erp JM, van Kessel DA, van den Bosch JM, van Oosterhout MF, Vink A.

J Heart Lung Transplant. 2009 May;28(5):531-2. doi: 10.1016/j.healun.2009.01.021. Epub 2009 Mar 14. No abstract available.

PMID:
19416789
38.

[Active donor treatment needed for more organ transplantations].

Nossent GD, Aerdts SJ, Kirkels JH, van de Graaf EA, van Kessel DA, van den Bosch JM, Erasmus ME.

Ned Tijdschr Geneeskd. 2009 Mar 28;153(13):623-7. Dutch. No abstract available.

PMID:
19408541
39.

18F-FDG PET in sarcoidosis: an observational study in 12 patients treated with infliximab.

Keijsers RG, Verzijlbergen JF, van Diepen DM, van den Bosch JM, Grutters JC.

Sarcoidosis Vasc Diffuse Lung Dis. 2008 Dec;25(2):143-9.

PMID:
19382534
40.

18F-FDG PET, genotype-corrected ACE and sIL-2R in newly diagnosed sarcoidosis.

Keijsers RG, Verzijlbergen FJ, Oyen WJ, van den Bosch JM, Ruven HJ, van Velzen-Blad H, Grutters JC.

Eur J Nucl Med Mol Imaging. 2009 Jul;36(7):1131-7. doi: 10.1007/s00259-009-1097-x. Epub 2009 Mar 4.

PMID:
19259660
41.

Rituximab in life threatening antisynthetase syndrome.

Vandenbroucke E, Grutters JC, Altenburg J, Boersma WG, ter Borg EJ, van den Bosch JM.

Rheumatol Int. 2009 Oct;29(12):1499-502. doi: 10.1007/s00296-009-0859-x. Epub 2009 Feb 1.

PMID:
19184665
42.

MUC1 568 A/G genotype-dependent cancer antigen 15-3 levels in breast cancer patients.

Kruit A, Tilanus-Linthorst MM, Boonstra JG, van Schaik RH, Grutters JC, van den Bosch JM, Ruven HJ.

Clin Biochem. 2009 May;42(7-8):662-5. doi: 10.1016/j.clinbiochem.2008.11.020. Epub 2008 Dec 24.

PMID:
19121298
43.

Soluble CD30 measured after lung transplantation does not predict bronchiolitis obliterans syndrome in a tacrolimus/mycophenolate mofetil-based immunosuppressive regimen.

Kwakkel-van Erp JM, Otten HG, Paantjens AW, van Kessel DA, van Ginkel WG, van den Bosch JM, van de Graaf EA.

J Heart Lung Transplant. 2008 Oct;27(10):1172-5. doi: 10.1016/j.healun.2008.06.007.

PMID:
18926413
44.

Serum thymus and activation regulated chemokine levels post-lung transplantation as a predictor for the bronchiolitis obliterans syndrome.

Paantjens AW, Kwakkel-van Erp JM, van Ginkel WG, van Kessel DA, van den Bosch JM, van de Graaf EA, Otten HG.

Clin Exp Immunol. 2008 Nov;154(2):202-8. doi: 10.1111/j.1365-2249.2008.03764.x. Epub 2008 Sep 8.

45.

The killer immunoglobulin-like receptor (KIR) group A haplotype is associated with bronchiolitis obliterans syndrome after lung transplantation.

Kwakkel-van Erp JM, van de Graaf EA, Paantjens AW, van Ginkel WG, Schellekens J, van Kessel DA, van den Bosch JM, Otten HG.

J Heart Lung Transplant. 2008 Sep;27(9):995-1001. doi: 10.1016/j.healun.2008.06.006.

PMID:
18765192
46.

[Pulmonary alveolar proteinosis: a disease caused by surfactant accumulation, and new treatment with sargramostim].

Huisman P, Grutters JC, van den Bosch JM.

Ned Tijdschr Geneeskd. 2008 Jun 28;152(26):1450-4. Dutch.

PMID:
18666660
47.

Imaging of fibrogenesis in patients with idiopathic pulmonary fibrosis with cis-4-[(18)F]-Fluoro-L: -proline PET.

Lavalaye J, Grutters JC, van de Garde EM, van Buul MM, van den Bosch JM, Windhorst AD, Verzijlbergen FJ.

Mol Imaging Biol. 2009 Mar-Apr;11(2):123-7. doi: 10.1007/s11307-008-0164-1. Epub 2008 Jul 30.

PMID:
18665424
48.

Increased expression of CD16, CD69, and very late antigen-1 on blood monocytes in active sarcoidosis.

Heron M, Grutters JC, van Velzen-Blad H, Veltkamp M, Claessen AME, van den Bosch JMM.

Chest. 2008 Nov;134(5):1001-1008. doi: 10.1378/chest.08-0443. Epub 2008 Jul 18.

PMID:
18641108
49.

CD14 genetics in sarcoidosis patients; who's in control?

Veltkamp M, Grutters JC, van Moorsel CH, Rijkers GT, Ruven HJ, Drent M, van den Bosch JM.

Sarcoidosis Vasc Diffuse Lung Dis. 2007 Sep;24(2):154-5. No abstract available.

PMID:
18496988
50.

Evaluation of CD103 as a cellular marker for the diagnosis of pulmonary sarcoidosis.

Heron M, Slieker WA, Zanen P, van Lochem EG, Hooijkaas H, van den Bosch JM, van Velzen-Blad H.

Clin Immunol. 2008 Mar;126(3):338-44. doi: 10.1016/j.clim.2007.11.005. Epub 2008 Jan 8.

PMID:
18182176

Supplemental Content

Loading ...
Support Center